Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MV-NIS + Atezolizumab in Metastatic NSCLC
NCT02919449Phase 1Terminated
- Sponsor
- Vyriad
- Start
- Aug 2017
- Primary completion
- Jan 2018
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MV-NIS in non-small cell lung cancer (NSCLC), sponsored by Vyriad. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Aug 2017; status: terminated.
02
Drugs
MV-NIS
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02919449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02919449.